Total Payments
$4,337
2024 Payments
$2,011
Companies
40
Transactions
221
Medicare Patients
12,045
Medicare Billing
$2.5M
Payment Breakdown by Category
Food & Beverage$4,256 (98.1%)
Education$81.31 (1.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,256 | 214 | 98.1% |
| Education | $81.31 | 7 | 1.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $547.54 | 28 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $319.80 | 16 | $0 (2024) |
| Janssen Biotech, Inc. | $319.59 | 19 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $260.06 | 16 | $0 (2024) |
| GENZYME CORPORATION | $255.18 | 12 | $0 (2024) |
| Merck Sharp & Dohme LLC | $241.61 | 11 | $0 (2024) |
| PFIZER INC. | $229.09 | 18 | $0 (2024) |
| Gilead Sciences, Inc. | $198.32 | 10 | $0 (2024) |
| SOBI, INC | $152.77 | 6 | $0 (2024) |
| Celgene Corporation | $146.05 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,011 | 96 | Novartis Pharmaceuticals Corporation ($248.29) |
| 2023 | $1,310 | 64 | Novartis Pharmaceuticals Corporation ($213.38) |
| 2022 | $262.77 | 15 | Amgen Inc. ($56.32) |
| 2021 | $23.29 | 1 | Seagen Inc. ($23.29) |
| 2020 | $50.55 | 3 | GENZYME CORPORATION ($21.81) |
| 2019 | $142.89 | 6 | Medtronic Vascular, Inc. ($67.66) |
| 2018 | $109.85 | 7 | PFIZER INC. ($45.75) |
| 2017 | $427.00 | 29 | PFIZER INC. ($107.26) |
All Payment Transactions
221 individual payment records from CMS Open Payments — Page 3 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.43 | General |
| 05/22/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $22.31 | General |
| Category: Hematology | ||||||
| 05/15/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $20.96 | General |
| 05/15/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $1.55 | General |
| 05/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ADVATE (Biological) | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: HEMATOLOGY | ||||||
| 05/10/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $19.47 | General |
| Category: Oncology | ||||||
| 05/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.85 | General |
| 05/08/2024 | PFIZER INC. | INLYTA (Drug), IBRANCE, XTANDI | Food and Beverage | In-kind items and services | $16.59 | General |
| Category: ONCOLOGY | ||||||
| 05/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $20.27 | General |
| 05/03/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.06 | General |
| Category: Hematology | ||||||
| 05/02/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $13.64 | General |
| Category: Oncology | ||||||
| 04/29/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug), PLUVICTO | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: Oncology | ||||||
| 04/26/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: Oncology | ||||||
| 04/24/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $22.96 | General |
| Category: Oncology | ||||||
| 04/17/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: Oncology | ||||||
| 04/15/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Oncology | ||||||
| 04/12/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $22.32 | General |
| Category: Hematology | ||||||
| 04/10/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 04/03/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $26.02 | General |
| Category: Oncology | ||||||
| 03/29/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Rare Disease | ||||||
| 03/20/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $28.85 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/19/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: Oncology | ||||||
| 03/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: Oncology | ||||||
| 03/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: ONCOLOGY | ||||||
| 03/11/2024 | GENZYME CORPORATION | CABLIVI (Biological), ENJAYMO | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 50 | 2,887 | 72,863 | $4.0M | $779,001 |
| 2022 | 55 | 2,705 | 75,398 | $3.9M | $527,366 |
| 2021 | 58 | 3,104 | 72,092 | $3.6M | $584,946 |
| 2020 | 65 | 3,349 | 76,139 | $4.2M | $650,566 |
Total Patients
12,045
Total Services
296,492
Medicare Billing
$2.5M
Procedure Codes
228
All Medicare Procedures & Services
228 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 14 | 8,400 | $1.1M | $361,940 | 31.6% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 19 | 3,834 | $893,620 | $127,964 | 14.3% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 44 | 51 | $244,902 | $55,966 | 22.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 248 | 564 | $207,552 | $49,660 | 23.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 1,560 | $102,720 | $28,492 | 27.7% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 16 | 9,400 | $188,000 | $22,081 | 11.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 71 | 193 | $136,451 | $18,891 | 13.8% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 81 | 89 | $94,963 | $15,146 | 15.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 76 | 76 | $53,884 | $11,757 | 21.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 116 | 235 | $73,555 | $10,905 | 14.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 249 | 801 | $51,264 | $8,290 | 16.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 270 | 878 | $17,560 | $7,375 | 42.0% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 12 | 54 | $198,450 | $7,293 | 3.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 259 | 816 | $29,376 | $6,195 | 21.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 12 | 88 | $18,568 | $4,772 | 25.7% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 59 | 25,100 | $50,200 | $4,115 | 8.2% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 39 | 45 | $29,565 | $4,059 | 13.7% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 80 | 89 | $73,069 | $3,810 | 5.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 62 | 251 | $27,108 | $2,864 | 10.6% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 129 | 206 | $12,360 | $2,752 | 22.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 23 | 52 | $17,888 | $2,524 | 14.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 22 | $7,854 | $2,005 | 25.5% |
| 83550 | Iron binding capacity | Office | 2023 | 129 | 206 | $7,210 | $1,765 | 24.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 30 | 65 | $10,205 | $1,402 | 13.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 41 | 128 | $12,288 | $1,357 | 11.0% |
About Dr. Nandita Rao, MD
Dr. Nandita Rao, MD is a Hematology & Oncology healthcare provider based in Plano, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1669507372.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nandita Rao, MD has received a total of $4,337 in payments from pharmaceutical and medical device companies, with $2,011 received in 2024. These payments were reported across 221 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($4,256).
As a Medicare-enrolled provider, Rao has provided services to 12,045 Medicare beneficiaries, totaling 296,492 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 228 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Plano, TX
- Active Since 02/22/2007
- Last Updated 12/11/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1669507372
Products in Payments
- KEYTRUDA (Biological) $221.98
- KISQALI (Drug) $206.92
- DARZALEX (Biological) $168.02
- OPDIVO (Biological) $156.53
- Lenvima (Drug) $142.94
- BESREMI (Drug) $133.10
- OJJAARA (Drug) $132.15
- VERZENIO (Drug) $120.24
- LUMAKRAS (Drug) $113.05
- REBLOZYL (Biological) $102.97
- Enhertu (Drug) $96.67
- MEKINIST (Drug) $94.69
- IMFINZI (Biological) $86.44
- CABLIVI (Biological) $79.37
- DOPTELET (Drug) $77.40
- SARCLISA (Biological) $74.26
- ENHERTU (Biological) $67.92
- ClosureFast (Device) $67.66
- LYNPARZA (Drug) $63.66
- VONVENDI (Biological) $62.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Plano
Ruben Saez, Md, MD
Hematology & Oncology — Payments: $117,913
Hematology & Oncology $117,913
Deepna Jaiswal, D.o, D.O
Hematology & Oncology — Payments: $50,892
Hematology & Oncology $50,892
Dr. Thuy Le, M.d, M.D
Hematology & Oncology — Payments: $22,323
Hematology & Oncology $22,323
Andrew Kovoor, Md, MD
Hematology & Oncology — Payments: $13,233
Hematology & Oncology $13,233
Virginia Kinsella, Md, MD
Hematology & Oncology — Payments: $13,129
Hematology & Oncology $13,129
Dr. Wendy Mahone-Johnson, Md, MD
Hematology & Oncology — Payments: $8,818
Hematology & Oncology $8,818